Abstract
The objective of the study: to describe the efficiency and safety of new ant i-t uberculosis drugs when treating tuberculosis patients with drug resistance. Subjects and methods. In Belarus, the retrospective and prospective analyses were performed in the cohort of 300 patients with multiple drug resistance and high rates of extensive drug resistance, who were treated with new drugs and drugs which were started to be used for the treatment of tuberculosis. In order to describe the cohort, blocks of variables were used to specify the efficiency and safety profiles of new ant i-t uberculosis drugs. Results of the study. The high level of therapeutic efficiency of new regimens and their fairly favorable safety profile were demonstrated in the cohort.
Highlights
The objective of the study: to describe the efficiency and safety of new anti-tuberculosis drugs when treating tuberculosis patients with drug resistance
In Belarus, the retrospective and prospective analyses were performed in the cohort of 300 patients with multiple drug resistance and high rates of extensive drug resistance, who were treated with new drugs and drugs which were started to be used for the treatment of tuberculosis
The high level of therapeutic efficiency of new regimens and their fairly favorable safety profile were demonstrated in the cohort
Summary
Цель исследования: характеристика профиля эффективности и безопасности использования новых противотуберкулезных лекарственных средств у пациентов с туберкулезом с лекарственной устойчивостью возбудителя. И более и требует ежедневного приема Проведен ретроспективный и проспективный лекарственных средств, которые являются более анализ когорты пациентов (n = 300), получавших токсичными, чем используемые для лечения ТБ с новые и перепрофилированные ПТЛС в Республилекарственной чувствительностью возбудителя, а ке Беларусь в период с 2015 г. Высокой частоты гибели пациентов (15,0%) и поте- Характеристика профиля эффективности новых ри для наблюдения (28,0%), что также, как прави- ПТЛС включала демографические данные и медило, обусловлено развитием нежелательных реакций, цинские показатели Это кон- с пациентами женского пола 85/300 (28,3%), что троль правильности применения этих препаратов, мониторинг безопасности пациентов, фармаконад-
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
